Bronchial hyperactivity is a recogn...

Bronchial hyperactivity is a recognized hallmark of asthma, characterized by way of an exaggerated bronchial response to numerous mediators, including histamine. It is also well recognized that bronchial hyperresponsiveness is increased following allergen front although no particular mediator has been shown to induce this answer The recent observation that PAF can induce increased nonspecific bronchial reactivity in normal make liables emphasizes its importance as an inflammatory mediator. In this report we sought to further elucidate the part of PAF in airway hyperractivity by the agency of comparing the effect of PAF upon methacholine-induced airway responsiveness in six non-asthmatic bring under rules Nonspecific airway responsiveness was not significantly increased following PAF inhalation at 6 hours nor was it increased at 1 2 7 or 14 days. Further elucidation of the potential part of PAF in explaining changes in airway reactivity is necessary.

Platelet-activating factor has lately assumed an important role in the pathogenesis of asthma,[1] particularly because PAF has been shown to increase nonspecific bronchial reactivity in animals[2-4] and humans.[5,6] The original observation according to Cuss et al[5] suggests a unique part for PAF that requires additional clarification. We sought to meditation the effect of inhaled PAF in nonasthmatic subjects

MATERIAL AND METHODS

We studied six nonasthmatic men aged 22 to 59 years. Demographic data are not absented in Table 1. The protocol was approved according to the Institutional Review Board of Creighton University and all bring under rules signed a consent form. [TABULAR DATA OMITTED]

[C.sub.16]-PAF and Lyso-PAF (Bachem Inc) were dissolved in 100 percent ethanol and diluted in phenol dolted saline solution and 0.25 percent human serum albumin. The final concentration of ethanol in the administered [C.sub.16]PAF or Lyso-PAF was les than 2 percent The inhalation of the saline diluent preced the inhalation of PAF or Lyso-PAF. A timed inhalation method[7] for 1 1 2 and 5 breaths of 200 [mu]g/ml followed by means of 2, 4, and 6 breaths of 1000 [mu]g/ml from a DeVilbiss 42 nebulizer was used. Using this timed regularity the subjects slowly inhaled medication starting from 25 percent of the inspiration capacity to 75 percent of inspiratory capacity, which make secures a consistent inhalation pattern for all doses.[7] The output of the nebulizer averaged 03 ml/actuation. The cumulative dose of PAF inhaled was 414 [mu]g Methacholine chloride (JT Baker Chemical), challenge was done at doses of 20 20 and 60 mg/ml with 10 breaths at the first pair doses and 5 breaths (x2) at 60 mg/ml for a cumulative total of 2460 mg (820 breath units [bu]) using the same inhalation protocol.[7] single breath of 1 mg/ml of methacholine equals 1 breath unit.

Baseline pulmonary function, including a forced vital capacity, was measured using a Collins 135-L Respirometer (Warren E Collins, Inc). Determination of changes induced on the challenge agent was determined using a forced partial expiration. This was performed at 50 percent of the baseline vital capacity. Vital capacity maneuvers were not performed after the initial baseline maneuver. The forced partial expiratory arise rate (pFEF) at 60 to 80 percent of the initial VC (pFEF 60-80%) was calculated from the partial volume/time curve

The three challenges were performed, with triplicates at each stair until a 40 percent change in the pFEF 60-80% occurr or until the last gradation of the respective challenges. The mean of the three pFEF 60-80% at each degree wsa used to determine if the [PDsub40] occurr (a 40 percent change decrease in pFEF 60-80% compared with saline solution control) The partial flow-volume measurement was done at three minutes after each dose of the three challenge agents.

The six bring under rules underwent a methacholine, Lyso-PAF, and PAF challenge within a seven-day period at the same time of day during phase 1 For phase 2 after a washout period of 14 to 30 days, the methacholine challenge was repeated, followed from a PAF inhalation of 10 breaths of 200 [mu]g/ml forward the subsequent day. M ethacholine challenges were then repeated at 6 h 1 2 7 and 14 days following PAF inhalation. The methacholine challenge at 1 2 7 and 14 days was done at the same time of the day as the challenge 6 h after PAF.

The eventuates of the methacholine, PAF and Lyso-PAF challenges are give utterance toed as the change in pFEF 60-80% compared with the column saline pFEF 60-80% for phase 1 The originates of the methacholine challenge post-PAF, during phase 2 were give utterance toed as the area under the dose reply curve. This is determined using a trapezoid arrangement (area = [x + y/2 x z])[8] The area for the methacholine challenge would be 82000 if a enthrall had a 0 percent fall in FEF 60-80% during the entire challenge (cumulative 820 bu) The area was necessary, as several enslaves did not have a 40 percent change in pFEF 60-80% to methacholine. The issues of the methacholine challenges are currented as the percent of the phase 2 rule methacholine day. An ANOVA analysis was used to compare the change in airway reactivity after PAF and the baseline pFEF 60-80% at the different days during phase 2 A p value [is les than or equal to]0.05 or les was considered significant.